Evaluation of Metabolic Changes in HCV Diabetic Patients Treated With Direct Acting Antiviral Agents

Abstract

Viral hepatitis is a major public health problem in need of urgent response. The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world. Seroprevalence was modeled to 10.6% and viraemic prevalence to 7.3% in 2014. The association between hepatitis C virus (HCV) infection and diabetes has been widely postulated. Prospective studies have demonstrated a higher risk of developing type 2 diabetes mellitus (T2DM) and insulin resistance in the HCV population. Uric acid production and metabolism are complex processes involving various factors that regulate hepatic production, as well as renal and gut excretion of this compound. The endogenous production of uric acid is mainly from the liver, intestines and other tissues like muscles, kidneys and the vascular endothelium. HCV particles in the peripheral blood are coated with lipids. About 108 HCV particles are assumed to be secreted from the liver into peripheral blood every 24 h.